The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Pneumococcal Infections Clinical Trial

Official title:

A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and PREVNAR 13® (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01513551
• Other study ID #: V114-002
• Secondary ID: 2011-004542-18V1
• Status: Completed
• Phase: Phase 2
• Start date: March 13, 2012
• Est. completion date: February 15, 2013

Study information

• Verified date: November 2018
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to see if an investigational vaccine for Streptococcus pneumonia disease (V114) has comparable safety, tolerability, and antibody response to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®) when administered to healthy adults 50 years of age or older.

The primary hypothesis is the serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) as measured by the pneumococcal electrochemiluminescence (Pn ECL) assay at one month postvaccination in subjects who receive V114 will be noninferior to those measured in subjects who receive PNEUMOVAX® 23.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 692
• Est. completion date: February 15, 2013
• Est. primary completion date: February 15, 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

-Without fever for 72 hours prior to vaccination

Exclusion Criteria:

• Prior receipt of any pneumococcal polysaccharide vaccine or any pneumococcal conjugate vaccine

• Known or suspected to be immunocompromised

• Functional or anatomic asplenia

• History of autoimmune disease

• Evidence of dementia or cognitive impairment

• Use of any immunosuppressive therapy

• Received a licensed non-live vaccine administered within the 14 days prior to receipt of study vaccine or scheduled to receive any other licensed vaccine within 30 days following receipt of study vaccine

• Received a licensed live virus vaccine within 30 days prior of receipt of study vaccine or is scheduled to receive any other licensed vaccine within 30 days of receipt of study vaccine

• Received any vaccine containing diphtheria toxoid within 6 months prior to receipt of study vaccine

• Received a blood transfusion or blood products within the 6 months before receipt of study vaccine or scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine

• History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease

• Received antibiotic therapy for any acute illness within 72 hours before receipt of study vaccine

Related Conditions & MeSH terms

• Pneumococcal Infections

Intervention

Biological:
• Pneumococcal Conjugate Vaccine (V114)
15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
• PNEUMOVAX® 23
23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
• PREVNAR 13®
13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With an Adverse Event	An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.	All AEs: up to 14 days after vaccination; Serious Adverse Events (SAEs): up to 6 months after vaccination
Primary	Percentage of Participants With an Injection-site Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups	Injection-site AEs reported by >=2% of participants in one or more vaccination groups were assessed.	Up to Day 14 postvaccination
Primary	Percentage of Participants With a Systemic Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups	Systemic AEs reported by >=2% of participants in one or more vaccination groups were assessed.	Up to Day 14 postvaccination
Primary	Percentage of Participants With a Serious Adverse Event	A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.	Up to 6 months postvaccination
Primary	Percentage of Participants With a Vaccine-related Serious Adverse Event	A SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs deemed by the investigator to be possibly, probably, or definitely related to study vaccine were reported.	Up to 6 months postvaccination
Primary	Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies	Pneumococcal serotype-specific IgG was measured in serum using an electrochemiluminescence (ECL) assay.	One month postvaccination
Secondary	Geometric Mean Titer (GMT) of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibodies	OPA for the serotypes contained in V114 was determined using a Multiplex Opsonophagocytic Assay (MOPA-4)	One month postvaccination